Background: Sagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer.
introduction
The majority of women who present with advanced ovarian cancer develop recurrent disease and die within 5 years despite responding to first-line therapy. Platinum-resistant recurrent ovarian cancer represents a great challenge, with only modest and short-term responses to treatment [1] . Consequently, there remains an outstanding need for effective therapies for patients with relapsed ovarian cancer, particularly platinum-resistant disease.
Sagopilone (ZK-EPO) is a fully synthetic epothilone that has demonstrated high activity in human tumour xenograft models of breast, ovarian, prostate, cervical and pancreatic cancer, non-small-cell and small-cell lung cancer, glioma and melanoma [2, 3] . In clinical trials, sagopilone has shown favourable tolerability with a low incidence of alopecia and diarrhoea and rarely reported clinically significant myelosuppression [4, 5] . Peripheral neuropathy that is generally mild to moderate is the predominant adverse event (AE) associated with treatment [4] . Sagopilone requires no premedication as it is not formulated with CremophorÒ EL (BASF, Ludwigshafen, Germany) and does not appear to have intrinsic hypersensitising properties [6] .
In a phase I/II study in women with recurrent platinum-sensitive ovarian cancer, sagopilone-carboplatin has shown promising antitumour activity [7] . In this article, we report results from a multicentre, prospective, open-label phase II trial of sagopilone in women with platinum-resistant ovarian cancer. In this trial, two different infusion times were used to assess whether infusion duration would affect neuropathy rates, following previous studies with microtubule-stabilising agents that reported a lower neuropathy incidence when drugs were infused over longer intervals [8, 9] .
patients and methods study design and objectives
This was a randomised, multicentre, prospective, two-arm, open-label phase II study conducted at 12 study centres in the UK (supplemental material, available at Annals of Oncology online). The primary objective was to investigate the efficacy of sagopilone in women with recurrent ovarian cancer progressing during, or within 6 months of the end of, platinum-based chemotherapy. Secondary objectives were to investigate the safety and tolerability of sagopilone and to assess the impact of the infusion duration on sagopilone tolerability.
Key eligibility criteria are detailed in the supplemental material (available at Annals of Oncology online). Patients must have adequately recovered from previous cancer therapy. Patients with residual neurotoxicity of grade 2 or more were excluded.
Patients were randomly allocated to two arms in which 16 mg/m 2 (to a maximum dose of 32 mg) sagopilone was administered as either a 3-h or a 0.5-h infusion. Patients were scheduled to receive one infusion of sagopilone every 3 weeks, with each 3-week cycle corresponding to one treatment course. Patients were to receive between two and six treatment courses. A Simon's two-step design was used to minimise the number of exposed patients in the event of inadequate efficacy [10] . For each arm, 13 patients were to be treated initially (step 1). A further 21 patients would be recruited per arm if there were ‡2 responders in the first 13 patients accrued (step 2). Sagopilone would be considered effective if ‡6 of the initial 34 patients in either arm responded.
The study followed the Declaration of Helsinki (1996) and Good Clinical Practice guidelines. The protocol and all protocol amendments were approved by an independent ethics committee at each centre. Written informed consent was obtained from each individual participating in this study.
results patient and treatment characteristics
A total of 63 women were randomly allocated to the study and treated (Table 1 ; supplemental Figure S1 and supplemental material, available at Annals of Oncology online). Treatment exposure was similar in the two arms, with a median of 3.0 cycles in the 0.5-h arm and 3.5 cycles in the 3-h arm.
During the trial, there was no delay in accrual while response assessment was ongoing, so the actual number of patients recruited exceeded the number specified by the trial design. In the 0.5-h arm, accrual was stopped when response data for the first 13 patients (primary analysis population) became available, resulting in a total of 25 patients. Recruitment into the 3-h arm continued to a total of 38 patients, the first 34 of whom comprised the primary analysis population.
The treatment arms were comparable with respect to demographic and baseline characteristics ( Table 1 ). The median platinum-free interval was 143 (range 32-217) days in the 0.5-h arm and 153 (range 28-216) days in the 3-h arm. A high percentage of patients (84% in the 0.5-h arm and 87% in the 3-h arm) had received a median of six cycles of prior taxane therapy.
safety
All 63 patients were assessable for safety. The majority of patients remained at World Health Organization performance status grade 0 or 1 throughout the study and scores in the two treatment arms were comparable. A total of 59 patients experienced one or more AEs related to the study drug; however, the majority (71%) were grade 1/2, with 29% experiencing grade 3 or more toxic effects. There were only two grade 4 events, pancytopenia and pain in extremity, which were attributed to sagopilone treatment. No acute allergic infusion reactions were observed.
There were 16 patients with dose reductions and/or postponements due to AEs in the 3-h treatment arm; 11 of these cases were due to peripheral neuropathy. In the 0.5-h treatment arm, seven patients had dose reductions and/or postponements; this was due to peripheral neuropathy in four patients.
The most common ( ‡10%) treatment-related AEs are listed in Table 2 . Peripheral sensory neuropathy was the most frequently observed AE, occurring in a total of 46 patients (73%) and in 10 patients (16%) at grade 3. A total of 14 patients (22%) had baseline findings indicating neurotoxicity (5 in the 0.5-h arm and 9 in the 3-h arm). The other most common drug-related grade 3 AEs were pain in extremity [four patients (6%)] and arthralgia [three (5%)]. Nausea [23 patients (37%)] and fatigue [22 (35%) ] were also frequently observed, although these were rarely reported above grade 1/2. Original inclusion criteria stated patients should have relapsed within 6 months of the end of the last platinum-based treatment. The protocol was later amended such that eligible patients had a maximum treatment-free interval of 6 months. Relapsing patients were not all restarted on treatment at exactly the time of relapse, resulting in some discrepancies in treatment-free interval of >180 days.
In general, the treatment arms were comparable with regard to the number of drug-related AEs, including peripheral sensory neuropathy [all grades: 0.5-h arm, 17 patients (68%); 3-h arm, 29 patients (76%)]. However, the intensity of neuropathy events differed between the arms, with grade 3 events observed in two (8%) and eight patients (21%) in the 0.5-and 3-h arms, respectively. Among other AEs, pain in extremity and vomiting occurred less frequently in the 0.5-h arm than the 3-h arm, while lethargy and abdominal pain occurred more frequently in the 0.5-h arm.
Analysis of the baseline data indicated that 32% and 42% of patients in the 0.5-and 3-h arms, respectively, had symptoms indicative of neurotoxicity at baseline, of whom 50% and 69%, respectively, experienced an increase in peripheral sensory neuropathy during the study. Conversely, 82% (0.5-h arm) and 82% (3-h arm) of patients without baseline neurotoxic findings experienced peripheral sensory neuropathy during the study. In total, 67% (0.5-h arm) and 76% (3-h arm) of patients who had prior taxane therapy experienced peripheral sensory neuropathy during the study. Of the nine taxane-naive patients enrolled, eight experienced peripheral sensory neuropathy during the study. Thus, these data suggest there is no significant difference in neuropathy between the two treatment arms.
The incidence of drug-related haematological AEs was low. One patient in each treatment arm experienced grade 3 anaemia. One patient experienced grade 3 neutropenia in the 0.5-h arm, and in the 3-h arm grade 4 pancytopenia and grade 3 thrombocytopenia were observed in one patient each.
In total, four deaths were reported during or within 4 weeks of the end of the study. None of the deaths were reported to be related to sagopilone and the cause of death was attributed to disease progression. efficacy A protocol amendment 1 year after the final study protocol, after 81% of patients had been entered, excluded patients with mucinous or clear-cell type carcinoma. These rare histological types are less responsive to chemotherapy than more common types and were excluded to give a more homogeneous population. This eliminated 5 of the 63 treated women from the efficacy analyses. A further patient was not assessable for efficacy as there was no histology available for her cancer at baseline. In total, 57 patients [23 (0.5-h arm) and 34 (3-h arm)] were assessable for efficacy and provided data for analysis: the per protocol population. These included 10 additional patients who had been recruited to the 0.5-h arm before primary analysis response results were known for the initial 13 patients.
The primary analysis population for efficacy evaluation according to the Simon's two-step design included all but these 10 additional patients [13 patients (0.5-h arm) and 34 patients (3-h arm)]. Six (13%) responders were identified in this population [one patient (0.5-h arm) and five patients (3-h arm)]. To conclude success in either arm of the study, at least six responders were required in that arm. The response rate was, therefore, insufficient to conclude success in either arm according to this criterion.
A secondary analysis was carried out to measure tumour response rates among the 57 assessable patients in the per protocol population. All 23 patients in the 0.5-h arm and 30 in the 3-h arm had measurable disease and were, therefore, assessable for modified RECIST (modRECIST) assessment. CA-125 assessment was only included in the efficacy analysis for patients with non-measurable disease [none (0.5-h arm) and four (3-h arm)]. In this analysis, there were nine confirmed responders [three (13%) in the 0.5-h arm and six (18%) in the 3-h arm; modRECIST (n = 8) or CA-125 only (n = 1)], at least five of whom had an improved response to sagopilone compared with the best response achieved with their last platinum-containing chemotherapy, which had been either stable disease or progressive disease (Table 3) . Five of the responders had paclitaxel-resistant disease [two (0.5-h arm) and three (3-h arm)]. There was an additional confirmed modRECIST responder in the 0.5-h arm with a response duration of 202 days; however, this patient was not included in the total number of responders because the time to relapse from last platinum therapy was 6.9 months. Similar response durations were observed in the two treatment arms (90-260 and 92-211 days in the 0.5-and 3-h groups, respectively).
As CA-125 response rates can be higher than those reported using RECIST, to avoid criticism, only patients with nonmeasurable disease had their responses assessed by CA-125 in the previous analysis. When patients with measurable disease and a baseline CA-125 measurement greater than twice the upper limit of normal were also included in the CA-125 assessment, responses in the per protocol population were as shown in Table 4 .
Time to progression (TTP), progression-free survival (PFS) and overall survival (OS) were also measured as secondary efficacy variables for the per protocol population. Median TTP was estimated as 78 days [95% confidence interval (CI) 45-137] for the 0.5-h arm and 91 days (95% CI 69-212) for the 3-h arm. 
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Similarly, median PFS was estimated to be 68 days (95% CI 42-86) for the 0.5-h arm and 91 days (95% CI 69-212) for the 3-h arm (Figure 1a) . Median OS was estimated as 238 days (95% CI 154-349) in the 0.5-h arm and 211 days (95% CI 143-340) in the 3-h arm (Figure 1b ).
discussion
In this study conducted in patients with platinum-resistant or refractory ovarian cancer, sagopilone showed clinical activity in terms of both radiological and CA-125 responses, suggesting that the drug may offer promise in this difficult-to-treat patient population [1] . The most common side-effect seen was peripheral sensory neuropathy. This is commonly observed with other microtubule-targeting agents, including other epothilones and taxanes [11] , and is, therefore, not unexpected with sagopilone treatment. Similar numbers of patients in each arm experienced drug-related peripheral sensory neuropathy. Of interest, however, was the observation of a trend towards greater intensity of these events in the 3-h arm compared with the 0.5-h arm, in contrast to results seen with taxanes and ixabepilone [8, 12] . Surprisingly, prior taxane therapy or neurotoxic events at baseline did not appear to increase the rate of peripheral sensory neuropathy developed during the study. In fact, patients without neuropathy at baseline had a higher incidence of peripheral neuropathy during the study. However, it may not be appropriate to base a conclusion on this analysis, which was not statistically powered and included a limited number of patients. A phase II trial is currently under way investigating the prophylactic use of acetyl-L-carnitine, a neuroprotective agent, in the prevention of sagopilone-induced neuropathy (http://ClinicalTrials.gov identifier: NCT00751205). Acetyl-L-carnitine has neuroprotective and neurotrophic properties and has been shown to be effective in treating chemotherapy-induced peripheral neuropathy in the clinic [13] .
An important finding from the study was the absence of acute allergic infusion reactions. Allergic reactions have been documented with the taxane anticancer agents paclitaxel and docetaxel, in addition to other epothilone therapies, and are usually attributed to their drug formulation vehicles, such as the nonionic surfactants CremophorÒ EL and polysorbate 80 [14, 15] . In contrast to other microtubule-stabilising agents, sagopilone does not require formulation with original article
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CremophorÒ EL, thus resulting in very rare hypersensitivity reactions [3] . The low incidence of haematological AEs in this study, and also in other studies with sagopilone, indicates the low propensity to cause myelosuppression [4, 6] and suggests that sagopilone may be a potentially good combination partner for drugs that are associated with bone marrow toxicity (e.g. carboplatin). The findings from this study in patients with ovarian cancer compare favourably with other second-line therapies used for this indication, such as topotecan, for which myelosuppression is a recognised concern requiring haematopoietic growth factors, transfusion therapy and schedule adjustments in order to reduce haematological toxicity and improve tolerance [16] .
Overall, the response rate was promising: 13% (6 of 47) in the primary analysis population and 16% (9 of 57) in the per protocol population. Furthermore, five of the responders had both platinum-and paclitaxel-resistant disease. The 0.5-h infusion of sagopilone did not appear to be inferior to the 3-h infusion. To date, there have been relatively few studies of other epothilones in ovarian cancer with which these findings can be directly compared. However, preliminary data are available for two epothilones: ixabepilone and patupilone [17] [18] [19] . In the ixabepilone study, 21 taxane-refractory patients with gynaecological malignancies received 40 mg/m 2 ixabepilone as a 1-h infusion every 21 days. Of these, two patients (one with ovarian carcinoma and one with endometrial carcinoma) responded to treatment, giving a response rate of 10% [17] . In a recently published phase I study evaluating 6.5-11.0 mg/m 2 patupilone given as a 20-min infusion every 3 weeks, the overall response rate by RECIST in 36 patients with resistant or refractory ovarian, primary fallopian or primary peritoneal cancer was 19.5% [19] . However, preliminary results from a phase II patupilone study of 112 women, 104 of whom had resistant or refractory ovarian cancer, were less positive [18] . Of these patients, who received 10.5 mg/m 2 patupilone administered via 10-to 20-min infusions every 3 weeks, eight had a partial response by RECIST, giving an overall response rate of 7.1%. A phase III trial is currently investigating the efficacy of patupilone in taxane-/platinum-resistant patients with ovarian cancer (http://ClinicalTrials.gov identifier: NCT00262990). In 829 patients randomly assigned to receive either patupilone (10 mg/m 2 i.v. q3 weekly) or pegylated liposomal doxorubicin (50 mg/m 2 i.v. q4 weekly), median PFS was 3.7 months in both arms [20] .
The 16% response rate with sagopilone also compares favourably with other agents approved as monotherapy for the treatment of platinum-resistant ovarian cancer. In the majority of published trials of paclitaxel, topotecan, liposomal doxorubicin or canfosfamide monotherapy in women with recurrent or resistant disease, response rates ranged from 3% to 13%, with a response rate of 22% observed in one paclitaxel study [21] [22] [23] [24] . In a phase II trial of weekly paclitaxel in patients with platinum-and paclitaxel-resistant ovarian cancer, the response rate was 20.9% [25] . In a phase II trial of trabectedin in patients with ovarian cancer, the response rate was 29% in the platinum-sensitive cohort and 6.3% in the platinum-resistant cohort [26] . In a phase II trial of pemetrexed, a response rate of 21% was reported in a platinum-resistant cohort [27] .
In conclusion, the results from our study indicate that sagopilone is effective with balanced tolerability in patients with recurrent ovarian cancer resistant to platinum compounds. Further trials will confirm the potential of sagopilone as a treatment of this indication. Annals of Oncology original article
